Finoriq research workspace
Vaxcyte, Inc. (PCVX) SEC Filings & Filing Highlights
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein. Review PCVX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Company
- Vaxcyte, Inc. (PCVX)
- Ticker
- PCVX
- Market Cap
- $8B
- Latest Price
- $55.45
- Industry
- Biotech & Pharma
Vaxcyte, Inc. (PCVX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Vaxcyte, Inc. (PCVX).
| Event | Form | Date |
|---|---|---|
| On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“th...On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Boar... | 8-K5.02 | 2026-06-23 |
| Broker Non-VotesOn June 15, 2026, Vaxcyte, Inc. (the “Company”) held its Annual Meeting of Stockholders. The following is a brief description of each matte... | 8-K5.07 | 2026-06-16 |
| Vaxcyte, Inc.: Earnings or resultsOn May 6, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text o... | 8-K2.02 | 2026-05-06 |
| Vaxcyte, Inc.: Corporate updateOn February 24, 2026, Vaxcyte, Inc. (“Vaxcyte”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Plac... | 8-K8.01 | 2026-02-24 |
| Vaxcyte, Inc.: Earnings or resultsOn February 24, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31... | 8-K2.02 | 2026-02-24 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.